Bristol-Myers Squibb (BMY) Tops Q1 EPS by 9c; Raises Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. SPY
9. SBUX
10. AXP

Go back to Bristol-Myers Squibb (BMY) Tops Q1 EPS by 9c; Raises Outlook

Bristol-Myers Squibb Co. (BMY) PT Raised to $53 at Deutsche Bank

April 27, 2018 9:19 AM EDT

Deutsche Bank raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $53.00 (from $52.00) while maintaining a Hold rating.

... More

Bristol-Myers Squibb (BMY) Reports Clinical Trial Collaboration with Advantagene Inc.

April 27, 2018 7:16 AM EDT

Advantagene, Inc. today announced that the company entered into a clinical trial collaboration with Bristol-Myers Squibb (NYSE: BMY) to evaluate the safety, tolerability, and preliminary efficacy of Advantagenes investigational Gene Mediated Cytotoxic Immunotherapy (GMCI, aglatimagene besadenovec + valacyclovir), in combination with Bristol-Myers Squibbs programmed death-1 (PD-1) immune checkpoint inhibitor, Opdivo (nivolumab), in newly diagnosed malignant glioma patients receiving standard of care (SOC) surgery and radiation with or without temozolomide. This study is being conducted in collaboration with leading... More